You are here: Welcome » Hélène Decaluwe

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
Both sides next revision
helene_decaluwe [2022/05/22 09:09]
liam 		helene_decaluwe [2022/09/20 03:45] (current)
liam [COVID-19]
Line 10: Line 10:
  
 She then completed her training in pediatric clinical immunology at the [[Necker Enfants-Malades Hospital]] in Paris, France with Professor [[Alain Fischer]]. Her research training includes a Master and a PhD degree in immunology at [[Pierre and Marie Curie University]] carried out in the laboratories of Professor [[Jean-Laurent Casanova]] and Professor [[James Di Santo]] respectively. She then completed her training in pediatric clinical immunology at the [[Necker Enfants-Malades Hospital]] in Paris, France with Professor [[Alain Fischer]]. Her research training includes a Master and a PhD degree in immunology at [[Pierre and Marie Curie University]] carried out in the laboratories of Professor [[Jean-Laurent Casanova]] and Professor [[James Di Santo]] respectively.
 +
 ===== Career and Affiliations ===== ===== Career and Affiliations =====
  
Line 19: Line 20:
  
 Decaluwe is a member of the [[National Advisory Committee on Immunization]] (NACI).((Public Health Agency of Canada. (2022, February 25). //National Advisory Committee on Immunization (NACI): Membership and representation.// Government of Canada. https://web.archive.org/web/20220318105951/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/naci-membership-representation.html#fn1-rf)) Decaluwe is a member of the [[National Advisory Committee on Immunization]] (NACI).((Public Health Agency of Canada. (2022, February 25). //National Advisory Committee on Immunization (NACI): Membership and representation.// Government of Canada. https://web.archive.org/web/20220318105951/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/naci-membership-representation.html#fn1-rf))
 +
 +===== Consulting =====
 +
 +Decaluwe was invited in April 2021 by [[pharmaceutical_companies:Eli Lilly]] to a Scientific Advisor Board on the role of baricitinib and monoclonal antibodies for the treatment of [[COVID-19]].
  
 ===== Research ===== ===== Research =====
  
-As a clinical researcher supported by the [[Fonds de Recherche du Québec en Santé]] (FRQS), she has dedicated her career to resolving the mechanisms of T cell differentiation in health, infection and primary immune deficiencies. The primary focus of her research is to better understand the role of cytokines in the differentiation of T cells in health and disease, and to develop novel immunotherapeutic approaches that target cytokine-dependent pathways and inhibitory receptors expressed on T cells, to cure chronic viral infections and cancer.+Decaluwe has dedicated her career to resolving the mechanisms of T cell differentiation in health, infection and primary immune deficiencies. The primary focus of her research is to better understand the role of cytokines in the differentiation of T cells in health and disease, and to develop novel immunotherapeutic approaches that target cytokine-dependent pathways and inhibitory receptors expressed on T cells, to cure chronic viral infections and cancer. 
 + 
 +==== Funding ==== 
 + 
 +She is funded by the [[Fonds de Recherche du Québec en Santé]] (FRQS), [[Canadian Institutes of Health Research]], [[National Institutes of Health]], [[Canadian Cancer Society]], [[Cole Foundation]], [[Charles Bruneau Foundation]], [[Leukemia and Lymphoma Society of Canada]], and the [[COVID-19 Immunity Task Force]]. 
 + 
 +She has also receiving funding from [[pharmaceutical_companies:Sobi]] for a study on a drug called Emapalumab.((Swedish Orphan Biovitrum. (2022, April 7). //A Two-cohort, Open-label, Single Arm, Multicenter Study to Evaluate Efficacy, Safety and Tolerability, PK and PD, of Emapalumab in Children and Adults With MAS in Still’s Disease or With MAS in Systemic Lupus Erythematous.// ClinicalTrials.gov. https://archive.ph/03Dxx)) 
 + 
 +==== COVID-19 ==== 
 + 
 +Decaluwe is a co-investigator on a research grant titled "Deciphering the immunopeptidomic landscape of COVID-19 disease" funded by the [[Canadian Institutes of Health Research]] through a [[COVID-19]] project grant.((Canadian Institutes of Health Research. (2021, March 1). //Deciphering the immunopeptidomic landscape of COVID-19 disease.// Canadian Research Information System. https://archive.ph/RTsEd)) 
 + 
 +She has applied for the CIHR-CEPI Leadership Award for Excellence in Vaccine Research for Infectious Diseases of Epidemic Potential, administered by the [[Canadian Institutes of Health Research]] and [[Coalition for Epidemic Preparedness Innovations]] (CEPI).((Public Health Agency of Canada. (2022, February 25). //National Advisory Committee on Immunization (NACI): Membership and representation.// Government of Canada. https://web.archive.org/web/20220318105951/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/naci-membership-representation.html#fn1-rf)) 
 + 
 +=== RECOVER === 
 + 
 +Decaluwe is a co-investigator in the REinfection in COVid-19 Estimation of Risk ([[RECOVER study]]), alongside [[Caroline Quach-Thanh]]. The study is funded by the [[Canadian Institutes of Health Research]], and the [[Public Health Agency of Canada]] through the [[COVID-19 Immunity Task Force]].((Racine, É., Boivin, G., Longtin, Y., McCormack, D., Decaluwe, H., Savard, P., Cheng, M. P., Hamelin, M.-È., Tadount, F., Adams, K., Bourdin, B., Nantel, S., Gilca, V., Corbeil, J., De Serres, G., & Quach, C. (2022). //The REinfection in COVID-19 Estimation of Risk (RECOVER) study: Reinfection and serology dynamics in a cohort of Canadian healthcare workers.// medRxiv, Preprint. https://doi.org/10.1101/2022.02.10.22269967)) ((Canadian Institutes of Health Research. (2020, June 1). //REinfection in COVid-19 Estimation of Risk (RECOVER).// Canadian Research Information System. https://archive.ph/3vdzt)) 
 + 
 +=== PITCH === 
 + 
 +Decaluwe is a co-Principal Investigator in the Persistence of T cell Immunity in Children with SARS-CoV-2 and Household contacts ([[PITCH Study]]), funded by the Children's Hospital Academic Medical Organization (CHAMO) innovation fund and the [[PSI Foundation]].((Decaluwe, H. //Post-doctoral fellowship in COVID-19 Immunology CHU Sainte-Justine Research Center Title: T cell responses in COVID-19 patients following infection and/or vaccination.// CHU Sainte-Justine Research Center. Retrieved May 22, 2022, from https://web.archive.org/web/20220522125556/https://research.chusj.org/RECHERCHE/files/71/717465d5-a2e8-42ac-8abf-509cb48c95b5.pdf)) 
 + 
 +=== CHOIR === 
 + 
 +Decaluwe is a Principal Investigator in the Children and Older Teens Immune Response to SARS-CoV-2 in Montreal ([[CHOIR study]]) alongside [[Caroline Quach-Thanh]] and [[Jesse Papenburg]], funded by the [[Canadian Institutes of Health Research]].((Canadian Institutes of Health Research. (2021, December 1). //CHOIR study: Children and Older Teens Immune Response to SARS-CoV-2 in Montreal.// Canadian Research Information System. https://archive.ph/Dgq1p)) 
 + 
 +===== Presentations ===== 
 + 
 +Decaluwe presented at the 76th Annual [[Canadian Society of Allergy and Clinical Immunology]] Scientific Virtual Meeting on the topic of hyperinflammation and targeted immunotherapies in hemophagocytic lymphohistiocytosis.((//76th Annual Canadian Society of Allergy and Clinical Immunology Scientific Virtual Meeting.// EMedEvents. Retrieved May 22, 2022, from https://www.emedevents.com/conferences/downloadbrochure/aHR0cHM6Ly93d3cuZW1lZGV2ZW50cy5jb20vdXBsb2Fkcy9jb25mZXJlbmNlcy9zZXNzaW9uX2Jyb2NodXJlLzhlNWM5Y2U0ZDBhYzMxNTI3YmQ4OTAzNDcwODJiMmY4LnBkZg==))
Back to top